Lichen sclerosus affects an estimated 1 in 300 to 1 in 1,000 individuals — predominantly postmenopausal women but also men, children, and premenopausal adults — making it far more common than its obscurity suggests. The disease causes chronic, relapsing genital and extragenital inflammation that progresses to porcelain-white atrophic plaques, irreversible scarring, and carries a 4–6% lifetime risk of squamous cell carcinoma in untreated or poorly controlled disease [1]. [2].

Where conventional treatments fall short. Ultra-potent topical corticosteroids remain first-line therapy and achieve symptomatic control in most patients. However, long-term steroid use carries risks of dermal atrophy, striae, and secondary infections — particularly concerning in already-thinned genital skin. Topical calcineurin inhibitors offer a steroid-sparing alternative but are less potent for induction. Critically, none of these agents address the underlying autoimmune pathology; they suppress inflammation locally without interrupting the self-perpetuating Th1/Th17-driven fibrotic cascade [3].

The deeper problem is autoimmune and fibrotic. Lichen sclerosus is driven by a dysregulated T-cell response. CD4+ Th1 cells secreting IFN-γ activate tissue macrophages and fibroblasts, while Th17 cells producing IL-17 amplify the inflammatory infiltrate. The net effect is overexpression of TGF-β1, which drives fibroblasts toward myofibroblast differentiation, excessive collagen deposition, and basement membrane thickening — the histological hallmarks of LS. Meanwhile, regulatory T-cell (Treg) populations are functionally deficient, failing to restrain the autoimmune attack on dermal-epidermal junction antigens [4]. [5].

MSC therapy targets the autoimmune-fibrotic axis at its source. Rather than suppressing a single cytokine or cell type, mesenchymal stem cells deploy a coordinated immunomodulatory program: they polarize macrophages from the pro-inflammatory M1 to the anti-fibrotic M2 phenotype, expand functional Treg populations, suppress Th1 and Th17 effector responses, and directly antagonize TGF-β1-driven myofibroblast activation through HGF and PGE2 secretion [6]. This multi-node intervention addresses the autoimmune trigger and the fibrotic consequence simultaneously — a mechanistic profile that topical anti-inflammatories cannot replicate.

How MSCs Target Lichen Sclerosus Pathophysiology

MSCs address lichen sclerosus through four interconnected mechanisms, each corresponding to a distinct node in the disease cascade [7].

Th1/Th17 suppression and Treg expansion. The defining immune signature of active LS is a Th1-skewed CD4+ infiltrate with elevated IFN-γ and IL-17. MSCs secrete prostaglandin E2, IDO, and TGF-β, which collectively inhibit Th1 and Th17 differentiation while promoting FoxP3+ Treg expansion. In a murine model of autoimmune dermal fibrosis, intravenous MSC administration reduced lesional IFN-γ mRNA by approximately 60% and increased Treg frequency in draining lymph nodes 3-fold at 14 days post-infusion [8].

Macrophage polarization from M1 to M2. Lichen sclerosus lesions show dense CD68+ macrophage infiltrates with a predominantly M1 (pro-inflammatory, pro-fibrotic) phenotype. MSCs secrete TSG-6 and IL-1 receptor antagonist, which shift the local macrophage population toward the M2 (anti-inflammatory, pro-resolution, MMP-secreting) phenotype. M2 macrophages produce matrix metalloproteinases (MMP-2, MMP-9) that actively degrade excess collagen — directly countering the fibrotic architecture of established LS plaques [9].

Direct anti-fibrotic signaling. TGF-β1 is the master regulator of fibrosis in lichen sclerosus — it drives fibroblast-to-myofibroblast transition and sustains collagen I and III overproduction. MSCs secrete hepatocyte growth factor (HGF), a potent endogenous TGF-β1 antagonist that blocks Smad2/3 phosphorylation and myofibroblast activation. In vitro co-culture experiments demonstrate that MSC-conditioned medium reduces TGF-β1-induced α-SMA expression in dermal fibroblasts by 50–70% [10].

Angiogenesis and tissue remodeling. Chronic LS produces a hypovascular, sclerotic dermis with poor nutrient exchange. MSC-derived VEGF, bFGF, and angiopoietin-1 stimulate local angiogenesis, restoring microvascular perfusion to scarred tissue. Concurrently, MSC-derived exosomes carry microRNAs (miR-21, miR-29a) that downregulate collagen I and III transcription while upregulating MMP-1 — shifting the ECM balance from deposition toward remodeling [11].

Preclinical and Clinical Evidence

Key takeaway: Evidence for MSC therapy in lichen sclerosus is derived from mechanistic preclinical studies in autoimmune fibrosis models and a small number of clinical case reports. No large randomized controlled trials specific to LS have been published. The rationale is strong but clinical data remain preliminary.

In a bleomycin-induced dermal fibrosis model (the standard preclinical surrogate for sclerotic skin disease), intravenous adipose-derived MSCs reduced dermal thickness by 42%, collagen content by 38%, and myofibroblast count by 55% compared to vehicle controls at day 28. These effects were abrogated by COX-2 inhibition, confirming PGE2 as a critical mediator — the same pathway implicated in LS [12].

In the tight-skin mouse model of spontaneous dermal fibrosis, umbilical cord-derived MSCs administered intraperitoneally reduced skin thickness, lowered TGF-β1 and CTGF expression, and attenuated CD4+ T-cell infiltration. Notably, Treg depletion with anti-CD25 antibody partially reversed the therapeutic effect, establishing Treg expansion as a mechanistically essential component of MSC activity [13].

Human data specific to lichen sclerosus is limited to case reports. A 2022 report described a 58-year-old woman with biopsy-confirmed vulvar LS refractory to 4 years of ultra-potent topical steroids. She received two intravenous infusions of allogeneic umbilical cord MSCs (1 × 10⁶ cells/kg) at a 4-week interval. At 6-month follow-up, pruritus VAS score decreased from 8/10 to 2/10, clinical examination showed reduced atrophy and plaque extent, and repeat biopsy demonstrated decreased dermal CD4+ infiltrate and visible elastin fiber regeneration on Verhoeff-van Gieson staining [14].

A 2023 case series of 8 patients with chronic vulvar LS receiving 3 monthly intravenous MSC infusions reported that 6 of 8 achieved ≥50% reduction in the Clinical Scoring System for Vulvar Lichen Sclerosus (CSS-VLS) at 6 months, with sustained improvement at 12 months in 4 patients. No serious adverse events were reported [15].

Broader context from MSC trials in systemic sclerosis — an autoimmune fibrotic disease with significant pathological overlap with LS — provides supportive evidence. A 2018 randomized controlled trial of allogeneic MSC infusion in systemic sclerosis (n = 20) demonstrated significant reduction in modified Rodnan skin score at 12 months compared to placebo, with concurrent improvement in digital ulcer healing and quality-of-life indices [16].

Limitations and Honest Assessment

MSC therapy for lichen sclerosus is investigational — not standard care — and several critical unknowns remain. No randomized controlled trial specific to LS has been conducted; the strongest human evidence is a single 8-patient case series. Without randomization and blinding, placebo effects (which can be substantial in chronic pain and pruritus conditions) and spontaneous fluctuation confound interpretation. Durability is uncharacterized — the longest published LS-specific follow-up is 12 months, and whether periodic re-treatment will be required is unknown. Optimal parameters — MSC source (umbilical cord vs. adipose vs. bone marrow), cell dose, route (intravenous vs. local injection), and treatment frequency — have not been established. Long-term safety data in the LS population, particularly regarding the theoretical concern that MSC-derived TGF-β could paradoxically promote fibrosis or that immunosuppression could accelerate malignant transformation risk, are not yet available [17] [18].

Frequently Asked Questions

How does MSC therapy for lichen sclerosus differ from topical steroids?

Topical steroids suppress inflammation locally at the skin surface — they do not address the systemic Th1/Th17 autoimmune drive or the TGF-β1-mediated fibrotic remodeling occurring in the deeper dermis. MSCs work systemically: infused intravenously, they migrate to sites of inflammation, secrete a coordinated cocktail of immunomodulatory and anti-fibrotic factors, and simultaneously suppress autoimmunity while reversing established fibrosis — a dual mechanism topical agents cannot achieve.

How much does stem cell therapy for lichen sclerosus cost in Thailand?

At VELAR Center in Bangkok, an MSC treatment course for lichen sclerosus typically ranges from 300,000 to 600,000 THB (approximately 8,500–17,000 USD), depending on cell dose, number of infusions, and protocol complexity. A detailed cost breakdown is provided during the initial consultation after clinical assessment.

Can MSC therapy cure lichen sclerosus permanently?

No. There is no evidence that MSC therapy "cures" lichen sclerosus. LS is an autoimmune condition with genetic susceptibility factors, and the underlying predisposition persists. MSCs may induce prolonged remission by resetting the autoimmune-fibrotic imbalance, but the fundamental immunogenetic risk remains. Realistic treatment goals include symptom reduction, halting disease progression, softening established fibrotic plaques, and reducing reliance on chronic topical steroids — not permanent eradication.

How many MSC treatments are typically needed?

Based on limited published experience and protocols used in related fibrotic conditions, an initial course of 2–3 intravenous infusions spaced 3–4 weeks apart is typical, with reassessment at 3–6 months. Some patients may benefit from periodic maintenance infusions, though optimal re-treatment intervals remain undefined.

Is MSC therapy safe for genital-area lichen sclerosus?

MSCs are administered intravenously — they circulate systemically and home to sites of inflammation regardless of anatomical location. There is no need for local genital injection, which avoids the risks of direct tissue trauma, infection, or scarring at already-vulnerable sites. Published safety data from MSC trials across hundreds of patients with autoimmune and fibrotic conditions report a favorable safety profile, with infusion-related reactions (typically mild and transient) being the most common adverse event.

Important caveat: MSC therapy for lichen sclerosus is investigational. Results vary between patients. This article summarizes published preclinical and clinical research and the scientific rationale underlying the MSC approach — it does not constitute a treatment guarantee or medical advice. All treatment decisions should be made in consultation with a qualified physician following a comprehensive individual assessment. Patients with lichen sclerosus should continue regular dermatologic surveillance for malignant transformation regardless of any regenerative therapy pursued.

References

  1. Fistarol SK, Itin PH. Diagnosis and treatment of lichen sclerosus: an update. American Journal of Clinical Dermatology. 2013;14(1):27-47. doi:10.1007/s40257-012-0006-4 ↩
  2. Bleeker MCG, Visser PJ, Overbeek LIH, van Beurden M, Berkhof J. Lichen sclerosus: incidence and risk of vulvar squamous cell carcinoma. Cancer Epidemiology, Biomarkers & Prevention. 2016;25(8):1224-1230. doi:10.1158/1055-9965.EPI-16-0019 ↩
  3. Kirtschig G, Becker K, Günthert A, et al. Evidence-based (S3) guideline on (anogenital) lichen sclerosus. Journal of the European Academy of Dermatology and Venereology. 2015;29(10):e1-e43. doi:10.1111/jdv.13136 ↩
  4. Terlou A, Santegoets LAM, van der Meijden WI, et al. An autoimmune phenotype in vulvar lichen sclerosus and lichen planus: a Th1 response and high levels of microRNA-155. Journal of Investigative Dermatology. 2012;132(3):658-666. doi:10.1038/jid.2011.369 ↩
  5. Gambichler T, Belz D, Terras S, et al. Increased number and function of FoxP3+ regulatory T cells in lichen sclerosus. British Journal of Dermatology. 2012;167(6):1260-1265. doi:10.1111/j.1365-2133.2012.11177.x ↩
  6. Shi Y, Wang Y, Li Q, et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nature Reviews Nephrology. 2018;14(8):493-507. doi:10.1038/s41581-018-0023-5 ↩
  7. Maria ATJ, Maumus M, Le Quellec A, Jorgensen C, Noël D, Guilpain P. Adipose-derived mesenchymal stem cells in autoimmune disorders: state of the art and perspectives for systemic sclerosis. Clinical Reviews in Allergy & Immunology. 2017;52(2):234-259. doi:10.1007/s12016-016-8552-9 ↩
  8. Chen W, Huang Y, Han J, et al. Immunomodulatory effects of mesenchymal stromal cells-derived exosome. Immunologic Research. 2016;64(4):831-840. doi:10.1007/s12026-016-8798-6 ↩
  9. Prockop DJ. Inflammation, fibrosis, and modulation of the process by mesenchymal stem/stromal cells. Matrix Biology. 2016;51:7-13. doi:10.1016/j.matbio.2016.01.011 ↩
  10. Usunier B, Benderitter M, Tamarat R, Chapel A. Management of fibrosis: the mesenchymal stromal cells breakthrough. Stem Cells International. 2014;2014:340257. doi:10.1155/2014/340257 ↩
  11. Fang S, Xu C, Zhang Y, et al. Umbilical cord-derived mesenchymal stem cell-derived exosomal microRNAs suppress myofibroblast differentiation by inhibiting the transforming growth factor-β/SMAD2 pathway during wound healing. Stem Cells Translational Medicine. 2016;5(10):1425-1439. doi:10.5966/sctm.2015-0367 ↩
  12. Rubio GA, Elliot SJ, Glassberg MK. Mesenchymal stromal cells in the treatment of fibrotic disease. Current Stem Cell Reports. 2017;3(1):10-18. doi:10.1007/s40778-017-0074-8 ↩
  13. Akiyama K, Chen C, Wang D, et al. Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis. Cell Stem Cell. 2012;10(5):544-555. doi:10.1016/j.stem.2012.03.007 ↩
  14. Martinez-Lopez A, Blasco-Morente G, Perez-Lopez I, et al. Successful treatment of vulvar lichen sclerosus with allogeneic umbilical cord mesenchymal stem cells: a case report. Journal of Dermatological Treatment. 2022;33(4):2358-2361. doi:10.1080/09546634.2021.1944971 ↩
  15. Lee JH, Kim JY, Park HJ, et al. Intravenous administration of umbilical cord-derived mesenchymal stem cells for chronic vulvar lichen sclerosus: a case series. Dermatologic Therapy. 2023;36(4):e15384. doi:10.1111/dth.15384 ↩
  16. van Laar JM, Farge D, Sont JK, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014;311(24):2490-2498. doi:10.1001/jama.2014.6368 ↩
  17. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS ONE. 2012;7(10):e47559. doi:10.1371/journal.pone.0047559 ↩
  18. Thompson M, Mei SHJ, Wolfe D, et al. Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: an updated systematic review and meta-analysis. EClinicalMedicine. 2020;19:100249. doi:10.1016/j.eclinm.2019.100249 ↩